文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

幽门螺杆菌感染后食管及近端胃癌发生率低

Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.
PubMed 文献 · Aliment Pharmacol Ther · 2020-03-04

本研究基于美国退伍军人事务部36 803例确诊幽门螺杆菌感染患者(中位年龄60.4岁,91.8%男性)的回顾性队列,评估未来食管及近端胃癌发生率及危险因素。结果显示感染后5、10、15年累积发生率分别为0.145%、0.26%、0.34%,年龄增长和吸烟与癌症风险相关,而亚洲或夏威夷原住民种族具有保护作用,幽门螺杆菌治疗及根除状态与癌症无关。

要点

  • 幽门螺杆菌感染后食管及近端胃癌15年累积发生率仅0.34%。
  • 年龄增长和吸烟是未来食管及近端胃癌的危险因素。
  • 幽门螺杆菌治疗或根除状态与未来癌症风险无关。

核心结论

  • 在美国幽门螺杆菌感染患者中,食管及近端胃癌发生率低。
  • 年龄增长和吸烟与未来癌症风险增加相关,亚洲或夏威夷原住民种族具有保护作用。
  • 幽门螺杆菌治疗及根除状态与未来食管及近端胃癌无关。

主要发现

  • 幽门螺杆菌检测后5、10、15年食管及近端胃癌累积发生率分别为0.145%、0.26%、0.34%。
  • 与白人相比,非洲裔美国人(SHR 0.87,95%CI 0.57-1.43)和美国印第安人(SHR 1.31,95%CI 0.18-9.60)风险相似,亚洲人(213例中无病例)和夏威夷原住民(295例中无病例)风险显著降低(P < .001)。
  • 年龄每增加5岁(SHR 1.17,95%CI 1.09-1.25,P < 0.001)和吸烟(SHR 2.06,95%CI 1.33-3.18,P = 0.001)与食管及近端胃癌风险相关。
  • 幽门螺杆菌治疗或根除状态与癌症风险无关(P > 0.20)。

临床怎么用

  • 对于幽门螺杆菌感染患者,食管及近端胃癌风险低,无需过度担心。
  • 应关注高龄和吸烟患者,加强监测。
  • 幽门螺杆菌治疗及根除不增加未来食管及近端胃癌风险。

局限性

  • 回顾性队列研究,可能存在未测量的混杂因素。
  • 研究人群以男性退伍军人为主,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Helicobacter pylori infection is the most important risk factor for non-proximal gastric adenocarcinoma, yet some posit it is protective against oesophageal adenocarcinoma and proximal gastric cancers. AIMS: To evaluate the incidence of and risk factors for future oesophageal and proximal gastric cancers, utilizing the largest North American cohort of patients with previously identified H pylori. Also to identify whether treatment and eradication of H pylori alter future oesophageal and proximal gastric cancer risk. METHODS: Retrospective cohort study within the Veterans Administration of 36 803 patients (median age 60.4 years; 91.8% male) with confirmed H pylori between 01 January 1994 and 31 December 2018. Primary outcome was diagnosis of future oesophageal and proximal gastric cancers. A time to event with competing risk analysis was performed, evaluating patient factors and whether the patient received H pylori treatment. Secondary analysis of those treated evaluated whether confirmed eradication was associated with cancer. RESULTS: The cumulative incidence of oesophageal and proximal gastric cancers 5, 10 and 15 years after H pylori detection was 0.145%, 0.26% and 0.34%. Risk of future oesophageal or proximal gastric cancer was similar amongst whites (reference), African Americans (SHR 0.87, 95%CI 0.57-1.43) and American Indians (SHR 1.31, 95%CI 0.18-9.60) but substantially reduced in those of Asian (no cases amongst 213 H pylori positive) or native Hawaiian origin (no cases amongst 295 H pylori positive) (P < .001). Increasing age (SHR 1.17 per 5 years, 95% CI: 1.09-1.25, P < 0.001) and smoking (SHR 2.06, 95% CI: 1.33-3.18, P = 0.001) were associated with oesophageal and proximal gastric cancers. Neither treatment of H pylori nor eradication status were associated with cancer (P > 0.20). CONCLUSIONS: In the largest study of US patients with H pylori, we demonstrate that rates of oesophageal and proximal gastric cancers after treatment of H pylori are low. Older age, and smoking are associated with future cancer, whilst Asian or Native Hawaiian race are protective. H pylori treatment and eradication are not associated with future cancer.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kumar S, Metz DC, Ginsberg GG, et al. Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection. Aliment Pharmacol Ther. 2020. PMID: 32133681. doi:10.1111/apt.15677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。